Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

被引：0

作者：

Bartlett, Nancy L. ^{[1
]}

Sehn, Laurie H. ^{[2
,3
]}

Matasar, Matthew ^{[4
]}

Schuster, Stephen J. ^{[5
]}

Assouline, Sarit ^{[6
]}

Giri, Pratyush ^{[7
]}

Kuruvilla, John ^{[8
]}

Canales, Miguel ^{[9
]}

Dietrich, Sascha ^{[10
]}

Fay, Keith ^{[11
,12
]}

Ku, Matthew ^{[13
]}

Nastoupil, Loretta ^{[14
]}

Wei, Michael C. ^{[15
]}

Yin, Shen ^{[15
]}

To, Iris ^{[15
]}

Huang, Huang ^{[16
]}

Min, Juliana ^{[17
]}

Bolen, Christopher R. ^{[15
]}

Penuel, Elicia ^{[15
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[7] Royal Adelaide Hosp, Adelaide, SA, Australia

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Hosp Univ La Paz, Madrid, Spain

[10] Heidelberg Univ, Heidelberg, Germany

[11] St Vincents Hosp, Sydney, NSW, Australia

[12] Royal North Shore Hosp, Sydney, NSW, Australia

[13] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] Genentech Inc, San Francisco, CA USA

[16] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[17] Roche Prod Ltd, Welwyn Garden City, Herts, England

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; mosunetuzumab; bispecific antibody; relapsed/refractory; follicular lymphoma; Phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-458

引用

页码：S453 / S453

页数：1

共 50 条

[1] Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/ refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal Phase II study
Dietrich, S.
Bartlett, N. L.
Sehn, L. H.
Matasar, M.
Schuster, S. J.
Assouline, S.
Giri, P.
Kuruvilla, J.
Canales, M.
Fay, K.
Ku, M.
Nastoupil, L.
Wie, M. C.
Yin, S.
To, I.
Huang, H.
Min, J.
Bolen, C. R.
Penuel, E.
Budde, L. E.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 211 - 212
[2] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/ Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit E.
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin Shen
To, Iris
Huang Huang
Min, Juliana
Bolen, Christopher R.
Penuel, Eliciaand
Elizabeth, Budde L.
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S44 - S44
[3] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta J.
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Huang
Min, Juliana
Penuel, Elicia
Budde, L. Elizabeth
BLOOD, 2022, 140 : 1467 - 1470
[4] Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory Follicular Lymphoma who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Budde, Elizabeth
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
Doral, Michelle Y.
Li, Chi-Chung
Huang, Huang
Negricea, Raluca
Penuel, Elicia
O'Hear, Carol
Bartlett, Nancy L.
El-Sharkawi, Dima
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 18 - 20
[5] Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After=2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study
Schuster, Stephen J.
Sehn, Laurie H.
Bartlett, Nancy L.
Matasar, Matthew
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Shadman, Mazyar
Cheah, Chan Y.
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Jiangeng
Kwan, Antonia
Penuel, Elicia
Budde, L. Elizabeth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S497 - S497
[6] Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after=2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study
Schuster, Stephen J.
Sehn, Laurie H.
Bartlett, Nancy L.
Matasar, Matthew
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Shadman, Mazyar
Cheah, Chan Y.
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta J.
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Jiangeng
Kwan, Antonia
Penuel, Elicia
Budde, L. Elizabeth
BLOOD, 2023, 142
[7] Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
Morschhauser, Franck
Bishton, Mark
Eyre, Toby A.
Bachy, Emmanuel
Cartron, Guillaume
Ysebaert, Loic
Bobillo, Sabela
Gutierrez, Norma C.
Budde, L. Elizabeth
Fox, Christopher P.
Knapp, Andrea
Yaqub, Manejeh
Wei, Michael C.
O'Hear, Carol
Li, Haocheng
Purev, Enkhtsetseg
Townsend, William
BLOOD, 2021, 138
[8] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Budde, L. Elizabeth
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
Doral, Michelle Y.
Li, Chi-Chung
Huang, Huang
Negricea, Raluca
Penuel, Elicia
O'Hear, Carol
Bartlett, Nancy L.
BLOOD, 2021, 138
[9] Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
Morschhauser, Franck
Bishton, Mark
Eyre, Toby A.
Bachy, Emmanuel
Cartron, Guillaume
Ysebaert, Loic
Bobillo, Sabela
Gutierrez, Norma C.
Budde, Elizabeth
Fox, Christopher P.
Knapp, Andrea
Yaqub, Manejeh
Wei, Michael C.
O'Hear, Carol
Li, Haocheng
Purev, Enkhtsetseg
Townsend, William
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 105 - 106
[10] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received.2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Budde, Elizabeth L.
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
Doral, Michelle Y.
Li, Chi-Chung
Huang, Huang
Negricea, Raluca
Penuel, Elicia
O'Hear, Carol
Bartlett, Nancy L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S387

← 1 2 3 4 5 →